Jing Xi

Jing Xi, MD, MPH

Third-year Fellow

Began fellowship in 2019


2003-2008 MD, Shanghai Medical College, Fudan University, China
2008-2010 MPH, University of Michigan, Ann Arbor, MI
Post-graduate Training
2016-2019 Resident/Chief Resident, Internal Medicine, St. Luke's Hospital, Chesterfield, MO
2010 Research Fellow, U.S. Food and Drug Administration (FDA), Silver Spring, MD
2011-2012 Research Associate, Institute of Medicine of The National Academies, Washington DC
2015-2016 Clinical Research Coordinator, Columbia University Medical Center, New York, NY
Editorial Responsibilities
2021-present Editorial Contributor, Elsevier PracticeUpdate (https://www.practiceupdate.com)
2004-2005 Excellent Medical Student Award, Fudan University
2010 FDA ORISE Research Fellow
2018 Podium Winner, National American College of Physician (ACP) poster presentation
2019 R25 STRENGTH Program, Washington University
2020, 2021 Chinese American Hematology and Oncology Network (CAHON) Young Investigator Award (YIA)


  • Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience
    Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A
    J Natl Compr Canc Netw 2021 Mar 24:1-8; [Epub ahead of print]
  • The Predictive Value of Absolute Lymphocyte Counts on Tumor Progression and Pseudoprogression in Patients With Glioblastoma
    Xi J, Hassan B, Katumba RGN, Khaddour K, Govindan A, Luo J, Huang J, Campian JL
    BMC Cancer 2021 Mar 16;21(1):285
  • Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    Xi J, Ma CX
    Curr Oncol Rep 2020 May 16;22(6):57
  • Neutrophil-To-Lymphocyte Ratio as a Predictor of Survival in Patients With Triple-Negative Breast Cancer
    Patel DA, Xi J, Luo J, Hassan B, Thomas S, Ma CX, Campian JL
    Breast Cancer Res Treat 2019 Apr;174(2):443-452
  • Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer
    Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, Bose R, Cherian M, Hernandez-Aya L, Frith A, Peterson L, Luo J, Krishnamurthy J, Ma CX
    J Natl Compr Canc Netw 2019 Feb;17(2):141-147

Book Chapters

  • Chapter 13. Breast Cancer
    Xi J, Ma CX, Clifton K
    In: The Washington Manual of Oncology, 4th Edition (Morgensztern D, Ghobadi A, Govindan R, Editors), Wolters Kluwer, Philadelphia, 2022
  • Chapter 1. Introduction and Content
    Chapter 4. Nature, Scope and Accomplishments of the CIRM Scientific Program

    Committee on Review of California Institute for Regenerative Medicine (CIRM), Stith-Butler A, Xi J
    In: Snyderman R (Ed), The California Institute for Regenerative Medicine: Science, Governance, and the Pursuit of Cures. (pp 18-28, 75-103). Washington DC: National Academies Press, 2012
  • Chapter 1. Introduction
    Chapter 3. Care of People With Pain
    Chapter 4. Education Challenges

    Committee on Advancing Pain Research, Care, and Education, Stith-Butler A, Xi J
    In: Briere R (Ed), Relieving Pain in America - A Blueprint for Transforming Prevention, Treatment, and Research (pp 19-55, 113-217). Washington, DC: National Academies Press, 2011